MAXY-4
Pre-clinical- Indications
- Autoimmune diseases, Transplant rejection
Company intelligence / Profile preview
Maxygen
Newark / Sunnyvale, California, United Statesmaxygen.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Maxygen offers custom protein engineering services using its proprietary molecular breeding directed evolution platform. The company collaborates with clients to design libraries of protein variants and identify improved proteins for applications such as gene therapy products, more accurate gene editing enzymes, and enhanced biomanufacturing processes. It does not develop or commercialize its own therapeutics.
- Modalities
- Recombinant proteinProteinEnzyme
- Industry
- Drug Discovery Services
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Maxygen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maxygen.